Globus Medical, Inc. $GMED Shares Purchased by Kennedy Capital Management LLC

Key Points

• Kennedy Capital Management boosted its stake in Globus Medical by 44.6% in Q3, acquiring 151,500 shares to hold 490,949 shares worth about $28.1 million, making GMED its 18th largest holding.
• Company insiders have been net sellers recently — EVP Kelly Huller sold 20,000 shares at $94.50 and CFO Kyle Kline sold 3,594 shares at $101.10, with insiders selling 35,594 shares (~$3.33 million) over the last 90 days while still owning 18.51% of the company.
• Globus beat expectations for the most recent quarter (EPS $1.28 vs. $1.06 est.; revenue $826.4M vs. $803.3M, up 25.7% YoY) and has seen rising analyst optimism and price targets (average target ~$104.36, multiple upgrades to "overweight"/"strong-buy").

Kennedy Capital Management LLC raised its position in shares of Globus Medical, Inc. (NYSE:GMED - Free Report) by 44.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 490,949 shares of the medical device company's stock after purchasing an additional 151,500 shares during the quarter. Globus Medical comprises 0.6% of Kennedy Capital Management LLC's portfolio, making the stock its 18th largest holding. Kennedy Capital Management LLC owned about 0.36% of Globus Medical worth $28,117,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of GMED. EverSource Wealth Advisors LLC grew its holdings in Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company's stock worth $27,000 after acquiring an additional 197 shares during the period. Advisors Asset Management Inc. bought a new position in shares of Globus Medical during the 2nd quarter valued at about $28,000. First Horizon Corp bought a new position in shares of Globus Medical during the 3rd quarter valued at about $31,000. Parallel Advisors LLC grew its stake in shares of Globus Medical by 45.1% in the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company's stock worth $32,000 after purchasing an additional 173 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Globus Medical in the 3rd quarter worth approximately $36,000. Institutional investors own 95.16% of the company's stock.

Insider Activity at Globus Medical

In related news, EVP Kelly Huller sold 20,000 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $94.50, for a total value of $1,890,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Kyle Kline sold 3,594 shares of Globus Medical stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $101.10, for a total value of $363,353.40. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 35,594 shares of company stock valued at $3,332,253. Company insiders own 18.51% of the company's stock.

Globus Medical Price Performance

NYSE GMED traded up $1.87 on Friday, hitting $86.38. 119,492 shares of the stock were exchanged, compared to its average volume of 1,320,894. The company's 50-day moving average price is $90.76 and its two-hundred day moving average price is $78.10. Globus Medical, Inc. has a 52-week low of $51.79 and a 52-week high of $101.40. The company has a market capitalization of $11.68 billion, a price-to-earnings ratio of 21.99, a P/E/G ratio of 2.04 and a beta of 1.05.

Globus Medical (NYSE:GMED - Get Free Report) last released its earnings results on Tuesday, February 24th. The medical device company reported $1.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.06 by $0.22. The company had revenue of $826.42 million during the quarter, compared to analyst estimates of $803.29 million. Globus Medical had a return on equity of 12.57% and a net margin of 18.30%.The company's revenue for the quarter was up 25.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.84 earnings per share. Equities analysts predict that Globus Medical, Inc. will post 3.44 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on GMED shares. Barclays increased their target price on shares of Globus Medical from $118.00 to $123.00 and gave the company an "overweight" rating in a research note on Wednesday, February 25th. TD Cowen raised Globus Medical to a "strong-buy" rating in a report on Tuesday, January 27th. Citigroup reiterated a "market perform" rating on shares of Globus Medical in a research report on Thursday, January 8th. Piper Sandler restated an "overweight" rating and issued a $115.00 target price (up from $90.00) on shares of Globus Medical in a report on Thursday, January 8th. Finally, Morgan Stanley upped their target price on Globus Medical from $70.00 to $100.00 and gave the company an "overweight" rating in a report on Tuesday, December 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $104.36.

More Globus Medical News

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research materially raised EPS forecasts across quarters and years (Q4 2026, Q1–Q3 2027, FY2026 and FY2027), including lifting FY2027 to ~$4.66 and several quarterly beats vs. prior Zacks views; Zacks carries a "Strong‑Buy" on GMED — this increases earnings visibility and underpins buy‑side interest. Zacks / MarketBeat Coverage
• Positive Sentiment: Brokerage consensus remains favorable: AmericanBankingNews reports an average rating of "Moderate Buy" from covering brokerages, reinforcing demand from institutional investors. Globus Medical Given Average Rating of "Moderate Buy" by Brokerages

About Globus Medical

Globus Medical, Inc NYSE: GMED is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.

Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical, Inc. (NYSE:GMED - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.